Argenx SE SEC filings ARGX
Argenx SE has 296 filings in SEC EDGAR's recent list, going back to Mar 1, 2017. Its latest annual report, Form 20-F, was filed on Mar 19, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 22, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F | Annual report (foreign issuer) | Mar 19, 2026 | Dec 31, 2025 |
| 20-F | Annual report (foreign issuer) | Mar 20, 2025 | Dec 31, 2024 |
| 20-F | Annual report (foreign issuer) | Mar 21, 2024 | Dec 31, 2023 |
| 20-F | Annual report (foreign issuer) | Mar 16, 2023 | Dec 31, 2022 |
| 20-F | Annual report (foreign issuer) | Mar 21, 2022 | Dec 31, 2021 |
| 20-F | Annual report (foreign issuer) | Mar 30, 2021 | Dec 31, 2020 |
| 20-F | Annual report (foreign issuer) | Mar 31, 2020 | Dec 31, 2019 |
| 20-F | Annual report (foreign issuer) | Mar 26, 2019 | Dec 31, 2018 |
| 20-F | Annual report (foreign issuer) | Mar 26, 2018 | Dec 31, 2017 |
Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ARGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Netherlands
- Headquarters
- Zwijnaarde
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1697862
- Former names
- argenx N.V (until Apr 21, 2017)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.